RESEARCH ARTICLE

The economic costs of malaria in pregnancy: evidence from four sub-Saharan countries [version 1; peer review: 1 approved, 1 approved with reservations]

Laia Cirera1*, Charfudin Sacoor2*, Martin Meremikwu3*, Louise Ranaivo4*, Manu F. Manun’Ebo5*, Dachi Arikpo6,7, Osvaldo Matavele2*, Victor Rafaralahy4, Didier Ndombe5, Clara Pons Duran1, Maximo Ramirez1, Francesco Ramponi1, Raquel González1,2,7, Christina Maly8, Elaine Roman8, Elisa Sicuri1,9, Franco Pagnoni1, Clara Menéndez1,2,7

1Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
2Manhiça Health Research Center, Manhiça, Mozambique
3Cross River Health and Demographic Surveillance System, University of Calabar, Calabar, Nigeria
4Malagasy Associates for Numerical Information and Statistical Analysis (MANISA), Antananarivo, Madagascar
5Bureau d'Étude et de Gestion de l'Information Statistique (BEGIS), Kinshasa, Democratic Republic of the Congo
6Institute of Tropical Diseases Research and Prevention, University of Calabar Teaching Hospital, Calabar, Nigeria
7CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
8Jhpiego, a Johns Hopkins University affiliate, Baltimore, USA
9London School of Economics and Political Science, London, UK

* Equal contributors

Abstract

Background
Malaria in pregnancy is a major public health problem in sub-Saharan Africa (SSA), which imposes a significant economic burden. We provide evidence on the costs of malaria care in pregnancy to households and the health system in four high-burden countries in SSA.

Methods
Household and health system economic costs associated with malaria control in pregnancy were estimated in selected areas of the Democratic Republic of Congo (DRC), Madagascar (MDG), Mozambique (MOZ) and Nigeria (NGA). An exit survey was administered to 2,031 pregnant women when leaving the antenatal care (ANC) clinic from October 2020 to June 2021. Women reported the direct and indirect costs associated to malaria prevention and treatment in pregnancy. To estimate health system costs, we interviewed health workers from 133 randomly selected health facilities. Costs were estimated using an ingredients-based approach.

Results
Average household costs of malaria prevention per pregnancy were USD6.33 in DRC, USD10.06 in MDG, USD15.03 in MOZ and USD13.33 in NGA. Household costs of treating an episode of uncomplicated/complicated malaria were USD22.78/USD46 in DRC, USD16.65/USD35.65 in MDG, USD30.54/USD61.25 in MOZ and USD18.92/USD44.71 in NGA, respectively. Average health system costs of malaria prevention per pregnancy were USD10.74 in DRC, USD16.95 in MDG, USD11.17 in MOZ and USD15.64 in NGA. Health system costs associated with treating an episode of uncomplicated/complicated malaria were USD4.69/USD101.41 in DRC, USD3.61/USD83.70 in MOZ and USD4.09/USD92.64 in NGA. These estimates resulted in societal costs of malaria prevention and treatment per pregnancy of USD31.72 in DRC, USD29.77 in MDG, USD31.98 in MOZ and USD46.16 in NGA.

Conclusions
Malaria in pregnancy imposes a high economic burden on households and the health system. Findings emphasize the importance of investing in effective strategies that improve access to malaria control and reduce the burden of the infection in pregnancy.

Keywords
malaria in pregnancy; economic burden malaria; household costs; health system costs
Key questions

- What is already known on this topic?
  - It has been argued that households’ costs associated with malaria treatment and prevention are important barriers to healthcare attendance.
  - Studies providing detailed evidence on the economic costs of malaria in pregnancy to the households and the health system in SSA are scarce and outdated.

- What are the new findings?
  - We investigated the economic costs to the households and the health system of malaria control in pregnancy in four endemic countries in SSA, with various contexts and endemicity levels among many other cultural differences and backgrounds.
  - Despite a commitment to universal healthcare in study countries, households face a significant financial burden associated to malaria in pregnancy, which is likely to impact the effectiveness of existing malaria control strategies.

- How this study might affect research, practice or policy
  - Results from this multi-country study will emphasize the importance of investing in strategies to improve access to malaria control tools and reduce the burden of the infection in pregnancy.

Introduction

Malaria in pregnancy (MiP) is a major contributor to maternal and neonatal mortality and morbidity in sub-Saharan Africa (SSA). Recommended strategies for MiP prevention in SSA by the World Health Organization (WHO), include insecticide-treated bed nets (ITNs) and provision of intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP) to all women from their second trimester of pregnancy.

Despite WHO’s recommendations and the strive for universal access to maternal health services, the coverage of these interventions remains low. According to the latest World Malaria Report, the coverage of 3 or more doses of IPTp (IPTp3+) is on average 32% in SSA.

Several barriers may affect the access and use of malaria control interventions in pregnancy, including difficult access to health facilities, sub-optimal quality of care and low availability of drugs. Household costs (direct and indirect) associated with malaria control may also constitute a significant barrier. Results from a meta-analysis described direct medical costs, acquisition of ITNs, and costs of drugs, diagnostic tests and registration fees, as important limitations to accessing malaria control tools in many SSA countries. Non-medical costs associated with routine antenatal care (ANC) visits, such as food, transport and opportunity costs of patients’ time, pose additional barriers leading to poor ANC attendance and low IPTp uptake in several contexts.

Nevertheless, available estimates on costs of treating and preventing MiP are outdated and only available in some specific contexts, compared to other malaria interventions. Representative and detailed up-to-date costing estimates of malaria in pregnancy in SSA, are essential to conduct further economic evaluations of malaria interventions, inform policy decisions and improve allocation of resources in the region.

This study aims at providing accurate estimates on the economic costs of malaria treatment and control in pregnancy to the households and the health system in high endemic areas. The study focuses on the Democratic Republic of Congo (DRC), Madagascar (MDG), Mozambique (MOZ) and Nigeria (NGA), countries which accounted for nearly half of worldwide malaria deaths in 2020.

Methods

Ethical considerations

Written informed consent was sought from all individuals who participated in the ANC exit survey and the questionnaire to the health workers, before conducting any study procedures. All study protocols and informed consents were approved by the Ethics Committee of the Hospital Clinic in Barcelona, the WHO ethics review board [(ERC.0003384 – 02/10/2020; CCI/051/AGO/2020 – 20/08/2020)]

Study setting

This costing study was part of a multi-country project to assess the effectiveness and cost-effectiveness of community-based delivery of intermittent preventive treatment (C-IPTp) of malaria during pregnancy. The study was conducted in 12 rural districts in four SSA countries: DRC, MDG, MOZ and NGA. The selection of these countries was based on criteria that included the existence of an operative system of community health workers (CHW), having IPTp policies in place, commitment from the Ministry of Health (MoH) and high malaria endemicity. The study areas were heterogeneous in terms of the demographic and health profiles, but all them were endemic of malaria, with the disease being among the leading causes of maternal and child mortality.

Study design and participants

The economic costs of malaria in pregnancy include the cost to the health system that provides prevention and treatment services, and the cost to households who access these services.

To collect the household costs of malaria in pregnancy, we administered an exit survey questionnaire to pregnant women when leaving a routine ANC visit from October 2020 to June 2021. Sample size for the minimum number of pregnant women to be interviewed was calculated as follows: $n \geq Z^2 \left( \frac{p_1-p_2}{\varepsilon^2} \right)$, where $Z$ is the critical value of the normal distribution at
level $\alpha=0.05$ (95% confidence level), $e$ is the margin of error ($e=0.05$) and $p$ is the households cost variability. Minimum sample size, assuming a 10% of dropout rate, resulted in 426 pregnant women interviewed per country.

To estimate the health system costs associated to control of MiP, interviews were administered to health workers from a random sample of 30% selected health facilities of existent facilities within the district. This resulted in a total of 133 health workers from 133 different health facilities being approached and interviewed, with any participant declining or withdrawing later on from the interview (see Table S1$^{13}$).

**Household costs**

All women leaving an ANC visit were approached for an interview. For those women that met the inclusion criteria, (i.e., being pregnant, living in the study area and leaving an ANC consultation), we sought written consent to participate. Participants were asked about the direct and indirect costs associated to attending a routine ANC visit, where malaria prevention services are provided. Direct costs (out-of-pocket expenses) were broken into medical (e.g., drugs and tests, registration fees), and non-medical costs (transportation and food while at health facility). Indirect costs reflected the value of the time lost due to attending an ANC visit. The average household cost of malaria prevention per pregnancy was calculated by multiplying the cost of providing malaria prevention services through an ANC visit by the average number of IPTp doses received$^{14}$.

Women who reported having experienced an episode of malaria in their current pregnancy (n=434) (Table S1$^{13}$), were asked about the direct (medical and non-medical) and indirect (value of time lost because of illness) costs associated to malaria treatment they had incurred. Uncomplicated malaria was defined as a confirmed malaria episode diagnosed at the outpatient clinic and not requiring hospital admission, while complicated malaria was defined as an episode of malaria requiring hospital admission. For inpatients cases, women were enquired about the costs incurred during hospitalization, length of stay and the presence of a caregiver while hospitalized and after discharge at home. The monetary value of women’s time lost was estimated by taking into consideration the average wage by activity sector and country (https://meusalario.org/mocambique/salario/sector-publico-mocambique/salarios-do-sector-de-saude)$^{15-21}$. For unemployed participants, studying or working in the informal sector, the minimum wage per country was considered. For women who had a caregiver while being admitted at the hospital or at home, the caregiver’s value of time lost was also included.

**Health system costs**

The health system costs associated to preventing malaria were retrieved and consist of the provision of IPTp and ITNs at the ANC visits. These costs included the costs of IPTp treatment with SP, the distribution of ITNs at the first ANC visit, personnel time and facilities running costs. Health personnel costs and health facility running costs were allocated to malaria prevention services based on an assessment of the proportion of time devoted to these services during an ANC visit. Reference prices for drugs and mosquito nets were taken from WHO and the Global Fund procurement prices. The average prevention costs per pregnancy were approximated by multiplying the costs of an ANC visit by the average number of IPTp doses received per women in intervention areas$^{14}$.

In addition, the health system costs of treating an episode of MiP, both for uncomplicated and complicated malaria, were estimated. The average cost of an uncomplicated case was defined as the costs of managing a malaria case in pregnancy as an outpatient, while the average costs of a complicated malaria episode were approximated by the average cost of a hospital admission case.

Recurrent (personnel salaries and time, medical supplies, etc.) and capital costs (utilities and running costs) associated with malaria treatment in pregnancy were estimated based on the average time and clinical staff involved in the management of MiP. WHO and the Global Fund procurement prices were used as reference prices for drugs, tests and vaccines$^{22-23}$. To estimate health facilities’ running costs, overall monthly expenses were allocated to a malaria case or an ANC visit, based on the proportion of malaria episodes or ANC visits of the total of outpatient visits. For health facilities with inpatient services (n=30), the cost per inpatient bed day was obtained from the WHO estimates$^{23}$. Total admission costs were calculated by multiplying the cost per inpatient bed day by the average number of admission days reported.

**Societal costs**

The societal cost of malaria care per pregnancy was estimated by including the costs of malaria prevention and treatment to the health system and households. The average treatment costs per pregnancy, both for the health system and households, were calculated by multiplying the treatment costs per malaria case (complicated and non-complicated) by the incidence of malaria (complicated and non-complicated) in pregnancy. We approximated the incidence of MiP by using self-reported data from pregnant women in intervention areas (Table S1$^{13}$).

**Data management and analysis**

Data was collected through standardized questionnaires using REDCap and data was directly entered after asking questions verbally to participants. Alternative applications to REDCap which are available for free include Qualtrics, among others. Stata 17 and Microsoft Excel 2019 were used to perform the costing calculations. Spearman’s rank correlation coefficient was used to assess the association between households’ time lost and overall costs associated to malaria control and treatment in pregnancy.

**Results**

**Household costs**

Out of the 2,617 pregnant women approached, 2,031 met the inclusion criteria and were interviewed (Table S1$^{13}$). The
mean participant’s age was 24 years (SD 6.4), with more than 80% of them being married or in union (Table S2\(^1\)). Most of the participants worked as subsistence farmers, except in NGA where almost 45% of respondents worked as small-scale traders or self-employed workers. The level of education varied by country, with DRC having the highest share of respondents with secondary and higher studies accomplished (67.7%), and Mozambique the lowest (9.6%). The percentage of women reporting having experienced an episode of malaria in their current pregnancy ranged between 8.8% in Madagascar and 42.7% in Nigeria.

Table 1 shows household costs associated to malaria prevention in pregnancy. The average household costs of attending an ANC visit, where malaria preventive measures in pregnancy are provided, such as ITNs or IPTp, were multiplied by the average IPTp doses received, resulting in average household prevention costs per pregnancy of USD6.33 in DRC, USD10.06 in MDG, USD15.03 in MOZ and USD13.33 in NGA. The indirect cost – time lost due to attending an ANC visit, with an average time loss of 3.5 hours/ANC visit – was the main contributor.

Overall, out of the 2,031 interviewed pregnant women, 73 (4%) experienced an episode of complicated malaria in their current pregnancy and 361 (18%) referred to having had an episode of uncomplicated malaria (Table S1\(^1\)). Household average cost associated with an episode of uncomplicated malaria was USD22.78 in DRC, USD16.65 in MDG, USD30.54 in MOZ and USD18.92 in NGA (Table 2). Regarding complicated malaria, household costs were USD35.65 in MDG, USD44.71 in NGA, USD46 in DRC and USD61.25 in MOZ (Table 3).

The indirect cost of treatment was the highest cost, both for complicated and uncomplicated malaria episodes (Table 2, Table 3 and Table S3\(^1\)). In Figure 1 and Figure 2, the plots of the total minutes lost due to an ANC visit (Figure 1) and the days lost due to an episode of malaria (Figure 2) against the overall households’ costs are shown. In both plots there is a strong association between the time lost and the overall households’ costs, with a Spearman’s rank correlation coefficient of 0.73.

Out-of-pocket (OOP) expenses, particularly the direct medical expenses associated to treatment and prevention of malaria in pregnancy, were found to be present across study countries (Table 2 and Table 3). More specifically, 22% (14 out of 63) of the women interviewed in DRC, 54% (23 out of 42) in MDG, 12% (10 out of 81) in MOZ and 33% (58 out of 175) in NGA, reported direct medical expenses when having an outpatient visit related to an uncomplicated malaria episode (e.g., tests, drugs and registration fees). For the admission cases, all women reported having incurred in direct medical expenses in all study sites.

### Table 1. Household costs of malaria prevention in pregnancy (USD 2018).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Household costs of malaria prevention in pregnancy (USD 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DRC (n=450)</td>
</tr>
<tr>
<td>Direct costs (out of pocket)</td>
<td>Mean</td>
</tr>
<tr>
<td>Direct non-medical costs(^1)</td>
<td>0.41</td>
</tr>
<tr>
<td>Direct medical costs(^2)</td>
<td>0.07</td>
</tr>
<tr>
<td>Indirect cost (Value of time lost)</td>
<td>1.94</td>
</tr>
<tr>
<td>Transport time (go and back)</td>
<td>108 minutes</td>
</tr>
<tr>
<td>Time at HF (waiting + consultation)</td>
<td>101 minutes</td>
</tr>
<tr>
<td>Value of 1 minute lost</td>
<td>0.009</td>
</tr>
<tr>
<td>Household costs malaria prevention per ANC visit</td>
<td>2.34</td>
</tr>
<tr>
<td>Average IPTp doses</td>
<td>2.70</td>
</tr>
<tr>
<td>Household costs malaria prevention per pregnancy</td>
<td>6.33</td>
</tr>
</tbody>
</table>

\(^{1}\) Includes travel costs to/from the health facility and non-medical costs at health facility (i.e., food and water, registration fees). In DRC, MDG, MOZ and NGA, 96%, 94%, 96% and 79% of women reported having walked to the HF, respectively

\(^{2}\) Includes medical costs at the health facility. In DRC, MDG, MOZ and NGA, 22%, 54%, 12% and 33% of women reported having spent some money at the HF, respectively

\(^{3}\) It includes the value of the time lost due to attending the ANC visit to receive malaria prevention services (transport+waiting time+consultation).
<table>
<thead>
<tr>
<th>Variable</th>
<th>DRC (n=63)</th>
<th>MDG (n=42)</th>
<th>MOZ (n=81)</th>
<th>NGA (n=75)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Direct costs of care-seeking</td>
<td>6.09</td>
<td>(5.09)</td>
<td>2.95</td>
<td>(2.89)</td>
</tr>
<tr>
<td>Direct non-medical costs(^1)</td>
<td>1.13</td>
<td>(3.86)</td>
<td>0.86</td>
<td>(1.57)</td>
</tr>
<tr>
<td>Direct medical costs(^2)</td>
<td>4.96</td>
<td>(4.48)</td>
<td>2.09</td>
<td>(2.41)</td>
</tr>
<tr>
<td>Indirect cost (Value of time lost)(^3)</td>
<td>16.69</td>
<td>(16.2)</td>
<td>13.70</td>
<td>(14.01)</td>
</tr>
<tr>
<td>Transport time (go and back)</td>
<td>101 minutes</td>
<td>136 minutes</td>
<td>169 minutes</td>
<td>58 minutes</td>
</tr>
<tr>
<td>Time at HF (waiting + consultation)</td>
<td>121 days</td>
<td>57 days</td>
<td>100 days</td>
<td>92 days</td>
</tr>
<tr>
<td>Value of 1 minute lost</td>
<td>0.010</td>
<td>0.007</td>
<td>0.015</td>
<td>0.015</td>
</tr>
<tr>
<td>Household costs per episode of uncomplicated MiP</td>
<td>22.78</td>
<td>(18.99)</td>
<td>16.65</td>
<td>(14.71)</td>
</tr>
</tbody>
</table>

DRC, Democratic Republic of Congo; MDG, Madagascar; MOZ, Mozambique; NGA, Nigeria; SD, standard deviation; HF, health facility; MIP, malaria in pregnancy.

\(^1\) Includes travel costs to/from the health facility and non-medical costs at health facility (e.g., food and water)

\(^2\) Includes medical costs at the health facility.

\(^3\) It includes the value of the time lost due to having an episode of malaria (transport, waiting time, diagnosis and consultation), as well as the value of the income foregone due to being unable to perform the normal economic activity. It also includes the loss of income for the caregiver. See table S3 for details.

---

<table>
<thead>
<tr>
<th>Variable</th>
<th>DRC (n=33)</th>
<th>MDG (n=7)</th>
<th>MOZ (n=2)</th>
<th>NGA (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Direct costs</td>
<td>13.522</td>
<td>(5.09)</td>
<td>8.08</td>
<td>(2.89)</td>
</tr>
<tr>
<td>Direct non-medical costs(^1)</td>
<td>5.66</td>
<td>(3.86)</td>
<td>2.76</td>
<td>(1.57)</td>
</tr>
<tr>
<td>Direct medical costs(^2)</td>
<td>7.86</td>
<td>(4.48)</td>
<td>5.32</td>
<td>(2.41)</td>
</tr>
<tr>
<td>Indirect costs (Value of time lost)(^3)</td>
<td>32.48</td>
<td>(18.99)</td>
<td>27.57</td>
<td>(14.71)</td>
</tr>
<tr>
<td>Transport time (go and back)</td>
<td>118 minutes</td>
<td>240 minutes</td>
<td>285 minutes</td>
<td>88 minutes</td>
</tr>
<tr>
<td>Days hospitalized</td>
<td>4 days</td>
<td>2 days</td>
<td>4 days</td>
<td>2 days</td>
</tr>
<tr>
<td>Value of 1 minute lost</td>
<td>0.009</td>
<td>0.009</td>
<td>0.015</td>
<td>0.014</td>
</tr>
<tr>
<td>Household costs per episode of complicated MiP</td>
<td>46.00</td>
<td>(23.44)</td>
<td>35.65</td>
<td>(11.18)</td>
</tr>
</tbody>
</table>

DRC, Democratic Republic of Congo; MDG, Madagascar; MOZ, Mozambique; NGA, Nigeria; SD, standard deviation; MIP, malaria in pregnancy.

\(^1\) Includes travel costs to/from the health facility and non-medical costs at health facility (e.g., food and water)

\(^2\) Includes medical costs at the health facility and treatment/drug costs after the health facility visit.

\(^3\) It includes the value of the time lost due to having an episode of complicated malaria and the loss of income for the caregiver. See table S3 for details.
**Figure 1.** Association between minutes lost due to receiving malaria preventive services at the ANC and household costs (in USD). ANC, antenatal care; DRC, Democratic Republic of Congo; MDG, Madagascar; MOZ, Mozambique; NGA, Nigeria.

**Figure 2.** Association between days lost due to being ill with malaria and household costs (in USD). DRC, Democratic Republic of Congo; MDG, Madagascar; MOZ, Mozambique; NGA, Nigeria.
77% of them (103 out of 133) patients with complicated malaria had to be transferred to the district hospital or other referral centres.

Table 4 presents the health system costs of preventing MiP through the ANC visits. The average health system costs per pregnancy were USD10.74 in DRC, USD16.95 in MDG, USD11.17 in MOZ and USD15.64 in NGA. Drugs (IPTp treatment with SP) constituted the largest share of cost, followed by insecticide treated nets (ITNs).

Provider costs for the treatment of an uncomplicated malaria episode in pregnancy were USD4.69 in DRC, USD3.61 in MDG, USD4.68 in MOZ and USD4.09 in NGA (Table 5). Case management of uncomplicated malaria was similar across study countries, with rapid diagnostic test (RDTs) being used as the main diagnostic tool, and artesunate-lumefantrine as the main first-line drug for treatment of uncomplicated malaria (Table S5).

Regarding complicated malaria, the treatment costs per episode were USD101.41 in DRC, USD63.33 in MDG, USD83.70 in MOZ and USD92.64 in NGA (Table 6). Differences in costs across countries were due to differences in hospital admission costs and number of admission days, with total admission costs per malaria case of USD88.16 in DRC, USD47.49 in MDG, USD64.20 in MOZ and USD77.33 in NGA (Table 6). Further details on the management of a complicated malaria episodes in pregnancy are presented in supplementary Table S6.

### Societal costs
As presented in Table 7, mean societal costs of malaria prevention and treatment per pregnancy were USD31.72 in DRC, USD29.77 in MDG, USD31.98 in MOZ and USD46.16 in NGA. If we assume that the proportion of pregnant women represents 4% of the total population, this would translate, for a targeted area with 100,000 inhabitants, into a yearly economic burden of malaria in pregnancy of USD126,874 in DRC, USD119,083 in MDG, USD127,901 in MOZ and USD184,620 in NGA.

### Discussion
In this study we have estimated costs associated with the treatment and prevention of malaria in pregnancy in four endemic countries in SSA from the perspective of the health provider and the households. The results showed that despite the international call to universal healthcare, in endemic SSA countries pregnant women and their families experienced a significant economic burden associated with attending routine ANC clinic visits to receive malaria prevention services and treatment for malaria. These expenses relate to the opportunity costs and the OOP costs, including direct medical and non-medical costs.

The main driver of household costs was the opportunity costs in terms of the value of the time lost due to care seeking or being ill with malaria. Across countries, it was observed that, including transport, waiting time and time at the consultation, women spent an average of 4 hours attending a routine ANC visit and 3.5 hours when seeking care for a malaria episode.

---

**Table 4. Health systems costs of preventing MiP (USD 2018).**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Health systems costs of preventing MiP (USD 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DRC (n=26)</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>Fansidar/SP</td>
<td>3.49</td>
</tr>
<tr>
<td>Mosquito nets¹</td>
<td>0.65</td>
</tr>
<tr>
<td>Health personnel²</td>
<td>0.64</td>
</tr>
<tr>
<td>Utilities and running costs³</td>
<td>0.18</td>
</tr>
<tr>
<td>Health system cost per ANC visit</td>
<td><strong>4.39 (0.36)</strong></td>
</tr>
<tr>
<td>Average IPTp doses</td>
<td>2.70</td>
</tr>
<tr>
<td>Health system cost per pregnancy</td>
<td><strong>10.74</strong></td>
</tr>
</tbody>
</table>

¹ Mosquito nets were reported to be distributed at the first ANC visit in all study sites.

² Based on average time of an ANC visit (34 min in DRC, 15 min in MDG, 24 min in MOZ and 42 min in NGA). 30% of health personnel costs allocated to malaria prevention services based on assessment of the proportion of time devoted to these services.

³ Monthly average costs of running the HF in each country were divided by the average monthly number of ANC visits. In addition, 30% of ANC overall running costs allocated to malaria prevention services based on assessment of the proportion of time devoted to these services.
Table 5. Health system costs associated with management of an episode of uncomplicated malaria in pregnancy (USD 2018).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Health systems costs associated to managing an episode of non-complicated MiP (USD 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DRC (n=26)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Drugs (including malaria treatment)</td>
<td>2.80 (2.3)</td>
</tr>
<tr>
<td>Lab. and diagnostic tests¹</td>
<td>0.94 (0.4)</td>
</tr>
<tr>
<td>Health personnel</td>
<td>0.68 (0.34)</td>
</tr>
<tr>
<td>Utilities and running costs¹</td>
<td>0.27 (0.33)</td>
</tr>
<tr>
<td>Total costs episode non-complicated MiP</td>
<td>4.69 (0.30)</td>
</tr>
</tbody>
</table>

1 99% of HFs use RDT as main diagnostic test. See table S5 for details.
2 Based on the average time of managing an episode of non-complicated malaria (36 min in DRC, 30 min in MDG, 46 min in MOZ and 49 min in NGA)
3 Monthly average costs of running the HF in each country were divided by the average monthly episodes of non-complicated malaria

Table 6. Health system costs associated with management of an episode of complicated malaria in pregnancy (USD 2018).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Health systems costs associated to managing an episode of non-complicated MiP (USD 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DRC (n=4)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Malaria treatment</td>
<td>9.16 (7.75)</td>
</tr>
<tr>
<td>Other drugs</td>
<td>2.21 (0.00)</td>
</tr>
<tr>
<td>Lab. and diagnostic tests¹</td>
<td>1.88 (0.00)</td>
</tr>
<tr>
<td>Hospital admission costs²</td>
<td>88.16 (48.81)</td>
</tr>
<tr>
<td>Total costs episode non-complicated MiP</td>
<td>101.41 (41.7)</td>
</tr>
</tbody>
</table>

1 99% of HFs use RDT as main diagnostic test. See table S6 for details.
2 Cost per inpatient bed day for primary hospitals obtained from WHO-CHOICE estimates (2010). Values updated to USD 2018. Estimates based on 80% occupancy rate, excluding drugs and diagnostics. It includes personnel costs while admitted at the hospital. We took the reference parameter for eastern and western Africa, respectively.

Outpatient episode. These figures reflect the households’ barriers in accessing health facilities, as well as the scarcity of resources at the health facilities, resulting in high user-to-staff ratios and long waiting times (Tables S3 and S4). Similar results have been reported in comparable contexts. These costs represent a high economic burden on households and may constitute a catastrophic cost, especially for the most vulnerable families. Considering the participants’ average monthly wage –USD90 in DRC, USD70 in MDG, USD143 in MOZ and USD135 in NGA – the average household costs associated with preventing and treating malaria per pregnancy represent between 22% and 43% of their monthly income.

The findings of this study are in alignment with results from an anthropological study conducted in the same intervention areas, whereby households’ OOP costs were identified as significant barriers to access facility-based care and treatment. OOP costs were particularly high in NGA, where OOP payments by users are a main mechanism for funding costs of treatments, tests and drugs provided at the health facility.

When compared to estimates from the literature, the household costs in this study are higher for the following reasons. First, our estimates assess the value of the time lost (opportunity cost) by considering the wage of each woman in her specific sector of employment, while in the other

Page 9 of 18
Table 7. Societal costs of malaria prevention and treatment in pregnancy (USD 2018).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Societal costs of malaria prevention and treatment in pregnancy (USD 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DRC</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>Household costs per pregnancy</td>
<td>12.89</td>
</tr>
<tr>
<td>Average prevention costs</td>
<td>6.33</td>
</tr>
<tr>
<td>Average treatment costs non-complicated malaria</td>
<td>3.19</td>
</tr>
<tr>
<td>Average treatment costs complicated malaria</td>
<td>3.37</td>
</tr>
<tr>
<td>Health system costs per pregnancy</td>
<td>18.83</td>
</tr>
<tr>
<td>Average prevention costs</td>
<td>10.74</td>
</tr>
<tr>
<td>Average treatment costs non-complicated malaria</td>
<td>0.66</td>
</tr>
<tr>
<td>Average treatment costs complicated malaria</td>
<td>7.43</td>
</tr>
<tr>
<td>Societal costs of malaria prevention and treatment per pregnancy</td>
<td>31.72</td>
</tr>
</tbody>
</table>

1 The incidence of self-reported non-complicated malaria during pregnancy was 14%, 7.55%, 14.92% and 36.31% in DRC, MDG, MOZ and NGA, respectively (table S1).  
2 The incidence of self-reported complicated malaria during pregnancy was 7.33%, 1.26%, 0.37% and 6.43% in DRC, MDG, MOZ and NGA, respectively (table S1).

In this study, data were gathered through a cross-sectional survey conducted among pregnant women when leaving an ANC visit. The costs collected captured the cost of preventive services provided at the ANC visits or outpatient visits but did not capture the complete health care pathway that the women may have received, especially if they suffered from repeated episodes of malaria or had adverse effects from MiP. Therefore, household costs estimated in this study should be considered as a lower bond of the true economic burden incurred by the pregnant women.

Conclusion

Results from this study demonstrate the significant economic burden that malaria infection imposes on both the household and the health system in endemic countries of SSA. Updated cost estimates from endemic areas are essential to inform economic evaluations for malaria control in pregnancy. Moreover, findings underline the need to explore alternative strategies to overcome the economic burden faced by pregnant women, such as community-based delivery approaches, and the importance of improving access to malaria care in pregnancy.

Data availability

Underlying data
figshare: Underlying_data. https://doi.org/10.6084/m9.figshare.21997595.v1
This project contains the following underlying data:

- Data file 1. “Exit_survey_database.csv”
- Data file 2. “Health_workers_database.csv”
- Data file 3. “Exit_survey_data_key.xls”
- Data file 4. “Health_workers_data_key.xls”
- Data file 5. “Households_costs_analysis.txt”
- Data file 6. “Health_system_costs_analysis.txt”

Extended data

figshare: Data Questionnaires and supplementary information
https://doi.org/10.6084/m9.figshare.21997529.v1

This project contains the following extended data:

- Data file 1. “Exit_survey_questionnaire.doc”
- Data file 2. “Health_workers_questionnaire.doc”
- Data file 3. “Supplementary_information.doc”

References


The paper is about the economic costs of malaria in pregnancy. The paper is well-written. The following are some general comments:

1. The authors say that they are estimating economic costs, but don't define how economic costs differ from financial ones. It would be helpful to define economic costs in the paper.

2. It is unclear how the districts and facilities were selected for the study in each country. What sampling was done in the selection of these? The authors should explain this so that the reader can assess whether these are representative in their countries.

3. No sensitivity analysis was conducted to account for uncertainty in the variable values. It is likely that there was some uncertainty in variable values or assumptions. Why wasn't this done?

Some specific comments are the following:

1. Pg. 4, second paragraph, do you mean to say that one health worker each from 133 facilities?

2. Pg. 4, fourth paragraph, "Women were enquired about the costs incurred...": 'enquired' could be changed to 'asked'.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Health economics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 20 Apr 2023

Laia Cirera

Thank you for the important comments on this study. Please, see below the answers and the correspondent changes in the manuscript based on your comments:

The authors say that they are estimating economic costs, but don’t define how economic costs differ from financial ones. It would be helpful to define economic costs in the paper.

- **Response:** Thanks for this relevant comment. Economic costs include both the financial costs (i.e. the direct expenditures on goods and services purchased, such as drugs, tests, transport or food) as well as the indirect cost, that is, the value of the time lost (opportunity cost). In the context of this study, we assumed that the opportunity cost is the women's value of the productivity lost due to going to the health facility. To better clarify this:
  - In line 12 we changed ‘financial burden’ for ‘economic burden’.
  - The methods section (lines 90-91) now includes the following sentence: “While direct costs reflect the financial costs, the economic costs include both direct and direct costs”

It is unclear how the districts and facilities were selected for the study in each country. What sampling was done in the selection of these? The authors should explain this so that the reader can assess whether these are representative in their countries.

- **Response:** Thanks for the comment. As specified in line 55, the study is part of a multi-country project to assess the effectiveness and cost-effectiveness of C-IPTp. As such, project countries and districts were selected by the project implementers in collaboration with governments. Selection was based on countries’ geographical diversity across WHO African region, a high burden of malaria, and the commitment of the government to implement C-IPTp, among others. Details on study areas are provided in another paper (Gonzalez et. al – Reference 11), which we have now also referenced in the Study setting (line 63). In addition, the criteria to conduct the
interviews to 30% of existent health facilities was based on the available budget, as this were the estimated maximum number of health facilities that could be reached. The 133 health facilities that were finally approached, were randomly selected within the list of existent health facilities in each district (lines 77-81).

No sensitivity analysis was conducted to account for uncertainty in the variable values. It is likely that there was some uncertainty in variable values or assumptions. Why wasn't this done?

**Response:** We see the reviewer's point and we agree that the information reported might be subject to uncertainty. As specified in line 55, this study is part of a a multi-country project to assess the effectiveness and cost-effectiveness of community-based delivery of intermittent preventive treatment (C-IPTp) of malaria during pregnancy. In the cost-effectiveness analysis of the intervention, which is part of a separate manuscript that will follow the publication of this manuscript, we provide accurate sensitivity analysis (one way and probabilistic sensitivity analysis), where key parameters are subject to uncertainty. Bearing this in mind, in this article the focus was rather on providing a disaggregated and accurate description of the economic costs associated to malaria in pregnancy, including the mean and also the standard deviation. These estimates conform the basis for conducting the main cost-effectiveness and sensitivity analysis.

.Pg. 4, second paragraph, do you mean to say that one health worker each from 133 facilities?-

**Response:** That's right. We have edited lines 78 and 79 accordingly in order to clarify this.

Pg 4. fourth paragraph, "Women were enquired about the costs incurred...": 'enquired' could be changed to 'asked'

**Response:** Thanks, this has been changed as suggested (line 100).

**Competing Interests:** No competing interests were disclosed.
Nigeria. Results from this multi-country study emphasize the importance of investing in strategies to improve access to malaria control and reduce the burden of malaria in pregnancy.

My comments are minor and only need to be clarified.

I suggest authors to explore more deeply the contexts of these four high-burden countries in SSA to better interpret the results (e.g. seasonality of transmission, major differences across study countries in health system characteristics, contextual factors, co-payment mechanisms between patients and providers, etc.). The Discussion needs to further explain these differences, which represent a rare opportunity to cost malaria care in pregnancy in low-income countries that have not received much attention in the literature. Despite these differences, is there a key message to policy makers emanating from these four settings?

The exit survey questionnaire to pregnant women has been administered when leaving a routine ANC visit from October 2020 to June 2021. The COVID-19 pandemic could have major adverse effects on the provision of health services for other major infectious diseases, such as malaria. Any assumptions about how the programmes for malaria prevention and treatment have been affected during this period of time? Care seeking reduced compared with pre-pandemic levels, prevention services partially suspended (LLIN mass campaigns halted, mass drug distribution or seasonal malaria chemoprevention interrupted, etc.)?

Please provide the exclusion criteria of participants: was there an age, co-morbidity limit?

The costs data have been obtained from a cross-sectional survey, a limitation of the study that has been underlined by the authors. Please explain briefly what data ideally would allow scholars to estimate the economic burden of malaria over the course of the entire malaria season and/or individual pregnancies to better reflect the impact of multiple episodes?

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.
**Reviewer Expertise:** Health Economics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 20 Apr 2023

Laia Cirera

We thank the reviewer for appreciating the study and for the comments. Please, see below our answers to the comments posed:

I suggest authors to explore more deeply the contexts of these four high-burden countries in SSA to better interpret the results (e.g. seasonality of transmission, major differences across study countries in health system characteristics, contextual factors, co-payment mechanisms between patients and providers, etc.). The Discussion needs to further explain these differences, which represent a rare opportunity to cost malaria care in pregnancy in low-income countries that have not received much attention in the literature. Despite these differences, is there a key message to policy makers emanating from these four settings?

**Response:** A full description of the setting has been provided in a separate manuscript (Gonzalez et al - Reference 11). We agree with the reviewer that the intervention areas included in this study are representative of the geographical diversity across the African region and reflect some of the hardest places to reach (in poor and remote contexts). Despite the differences across study areas, our results do provide a clear message to policymakers and emphasize the importance of investing in strategies that reduce the economic burden faced by pregnant women and improve access to malaria care in pregnancy. To emphasize this message, at the beginning of the conclusion the following sentence has been added (line 330): “Despite the contextual differences across study areas, results from this study demonstrate the significant economic burden that malaria infection imposes on both the household and the health system in endemic countries of SSA.”

The exit survey questionnaire to pregnant women has been administered when leaving a routine ANC visit from October 2020 to June 2021. The COVID-19 pandemic could have major adverse effects on the provision of health services for other major infectious diseases, such as malaria. Any assumptions about how the programmes for malaria prevention and treatment have been affected during this period of time? Care seeking reduced compared with pre-pandemic levels, prevention services partially suspended (LLIN mass campaigns halted, mass drug distribution or seasonal malaria chemoprevention interrupted, etc.)?

**Response:** We see the reviewer's point. The COVID-19 outbreak in Mozambique occurred during the study data collection (October 2020 to June 2021) and therefore, these results have been seen in light of such a big shock, which might have affected our results. Despite this, the implementation of the study went ahead (C-IPTp distribution) and the intervention (adopting full safety measures) continued to be implemented without major disruptions.

Please provide the exclusion criteria of participants: was there an age, co-morbidity limit?

**Response:** We agree with the reviewer. The inclusion criteria of participants has been
clarified and the 2nd paragraph of the “Study design and participants” now reads as (lines 71-72): “As such, only women of reproductive age, being pregnant and after leaving a routine ANC visit were selected to participate.

The costs data have been obtained from a cross-sectional survey, a limitation of the study that has been underlined by the authors. Please explain briefly what data ideally would allow scholars to estimate the economic burden of malaria over the course of the entire malaria season and/or individual pregnancies to better reflect the impact of multiple episodes?

- **Response:** A longitudinal study following up a cohort of pregnant women over the malaria season would have been ideal to effectively capture the full costs of malaria in pregnancy and reflect the economic burden of multiple infections during the same pregnancy. To emphasize this, in the discussion the following sentence has been added (lines 325-326): “A longitudinal study design would have better captured the full costs of malaria in pregnancy.”

**Competing Interests:** No competing interests were disclosed.